Pre-made Glembatumumab Vedotin benchmark antibody (Whole mAb ADC, anti-GPNMB therapeutic antibody, Anti-HGFIN/NMB/PLCA3 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Glembatumumab Vedotin benchmark antibody (Whole mAb ADC, anti-GPNMB therapeutic antibody, Anti-HGFIN/NMB/PLCA3 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Glembatumumab vedotin (also known as CDX-11 and CR11-vcMMAE) is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB).
| Products Name (INN Index) | Pre-Made Glembatumumab Vedotin Biosimilar, Whole Mab Adc, Anti-Gpnmb Antibody: Anti-HGFIN/NMB/PLCA3 therapeutic antibody Drug Conjugate |
|---|---|
| INN Name | glembatumumab vedotin |
| Target | GPNMB |
| Format | Whole mAb ADC |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 – kappa |
| VD LC | IgG2 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Celldex Therapeutics,?Inc. (Needham MA USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | Abgenix's XenoMouse? |
| Previous Name | NA |
| Gm Offical Target Name | GPNMB |
| Package |
